Saudi Press

Saudi Arabia and the world
Thursday, Jul 24, 2025

Vaccine business: The days of free vaccines may soon end in the U.S.

Vaccine business: The days of free vaccines may soon end in the U.S.

The U.S. government is planning to stop paying for COVID-19 vaccines and treatments, and shift the bill onto the health care industry and eventually the consumer—possibly making it one of the first countries to end the practice of giving out coronavirus vaccines for free.

The Department of Health and Human Services will hold a planning session on Aug. 30, the Wall Street Journal reported, to bring together representatives from the health care industry as well as state health departments, to discuss the commercialization of COVID-19 treatments.

The move comes a few days after White House COVID-19 Response Coordinator Dr. Ashish Jha confirmed on Tuesday that the Biden Administration had taken steps to get past the crisis phase of the pandemic and stop buying vaccines, treatments, and tests as early as fall.

“One of the things we’ve spent a lot of time thinking about in the last many months…is getting us out of that acute emergency phase where the U.S. government is buying the vaccines, buying the treatments, buying the diagnostic tests,” Jha said at an event sponsored by the U.S. Chamber of Commerce Foundation.

“My hope is that in 2023, you’re going to see the commercialization of almost all of these products. Some of that is actually going to begin this fall, in the days and weeks ahead,” Jha said.

It was always the plan under both the Trump and Biden administration to push the pricing and coverage control of COVID-19 vaccines and treatments onto the healthcare industry.

As COVID cases drop and the pandemic response funding runs short, the U.S. is determined to privatize COVID-19 treatment by the end of the year.

“We’ve known at some point we’d need to move over into the commercial market, and we’re approaching that time now,” Dawn O’Connell, assistant secretary at HHS for preparedness and response, told the WSJ.


How it will work


The move to shift payments for COVID-19 drugs to the commercial market may still take months.

At the upcoming HHS meeting, company representatives and officials still need to discuss reimbursement and coverage, as well as regulatory, market dynamic, and equity issues.

Insurers and pharmacy benefit managers negotiating with drug manufacturers means prices would rise higher than what the federal government paid.

With each insurer paying for the vaccine, premiums are also likely to rise for the consumer, Larry Levitt, executive vice president for health policy at the Kaiser Family Foundation, told the WSJ.

“Without the government purchasing vaccine doses in advance, the U.S. may fall behind other countries in getting quick access to boosters and new variant-specific vaccines,” Levitt said.

A key point of the meeting will be discussing how the 30 million uninsured Americans will access COVID-19 resources.

“Right now everybody can walk into CVS and get a vaccine. I want to make sure when we make this transition, we don’t end up in a point where nobody can get a vaccine because we didn’t get the transition right,” Jha said at the event on Tuesday.

The move also might create a challenge for those suffering from long COVID, which is known to increase the risk of cognitive deficit (also known as brain fog), psychotic disorders, and epilepsy for two years after a COVID diagnosis, according to a study published in The Lancet Psychiatry on Wednesday.


Wrestling for funding


The Biden administration asked Congress in April for $10 billion to fund the ongoing pandemic response efforts. After failing to persuade Congress, White House officials said they would have to repurpose federal COVID-19 funds to supply more antiviral pills and vaccines.

As funding in government faltered, pharmaceutical companies have been eagerly watching the situation, as commercialization of COVID-19 treatments could bring a windfall worth billions of dollars in profits.

The 10 largest pharmaceutical companies by revenue brought in a collective $734.8 billion in revenue and $130.6 billion in profits in 2021, according to the 2022 Fortune Global 500, from the 12.2 billion doses that have been administered globally as of July 17.


Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Russia Formally Recognizes Taliban Government in Afghanistan
Mediators Edge Closer to Israel-Hamas Ceasefire Agreement
Emirates Airline Expands Market Share with New $20 Million Campaign
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
Amazon Reaches Major Automation Milestone with Over One Million Robots
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
China Unveils Miniature Insect-Like Surveillance Drone
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Iran Executes Alleged Israeli Spies and Arrests Hundreds Amid Post-War Crackdown
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
Iran's Parliament Votes to Suspend Cooperation with Nuclear Watchdog
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
NATO Leaders Endorse Plan for Increased Defence Spending
U.S. Crude Oil Prices Drop Below $65 Amid Market Volatility
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Oman Set to Introduce Personal Income Tax, First in Gulf
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Iran Intensifies Crackdown on Alleged Mossad Operatives After Sabotage Claims
Trump Praises Iran’s ‘Very Weak’ Response After U.S. Strikes and Presses Israel to Pursue Peace
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
G7 Leaders Fail to Reach Consensus on Key Global Issues
Mass exodus in Tehran as millions try to flee following Trump’s evacuation order
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
×